Evidence map›Paper›PMID 41168527›Full record

ArticleThe AAPS journal2025

The Role of Early Exposure Metrics (pAUC

Li-Feng Hsu

Abstract read
PubMed Publisher
In one paragraph

Article in The AAPS journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Li-Feng HsuSchool of Pharmacy, National Defense Medical Center, Taipei, Taiwan (R.O.C.). Lfhsu@cde.org.tw.ORCID 0000-0002-6268-3500

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methylphenidate extended-release (ER) products are used in the treatment of attention-deficit/hyperactivity disorder (ADHD). These products exhibit diverse pharmacokinetic (PK) profiles that influence early systemic exposure and clinical response. To ensure bioequivalence (BE) for products such as Concerta and Ritalin LA, both the FDA and EMA recommend the use of pAUC

Indexed as

Attention Deficit Disorder with HyperactivityCentral Nervous System StimulantsMethylphenidateModels, BiologicalComputer SimulationDelayed-Action PreparationsHumansTherapeutic EquivalencyCentral Nervous System StimulantsDelayed-Action PreparationsMethylphenidateBioequivalenceExtended-release ProductsMethylphenidatePartial area under the curve (pAUC)

Identifiers

PMID41168527

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.